# Risk Assessment: MORN (Morningstar, Inc.)

## Fecha: 2026-02-12

## Risk Score: MEDIUM

---

## Matriz de Riesgos

| # | Categoria | Riesgo | Probabilidad | Impacto | Score | Mitigante |
|---|-----------|--------|-------------|---------|-------|-----------|
| 1 | Valoracion | EPS peak risk -- P/E of 18x may be on inflated earnings | Media | Alto | HIGH | EPS CAGR +24% is unsustainable; normalized P/E may be 22-25x on lower earnings |
| 2 | Fundamental | CRSP acquisition conflict of interest erodes brand trust | Media | Alto | HIGH | CRSP completed Feb 2026, $3.2T in Vanguard assets benchmarked; structural conflict |
| 3 | Fundamental | AI disruption of traditional investment research | Media | Medio | MEDIUM | MORN integrating AI (Intelligence Engine), but risk of commoditization is real |
| 4 | Fundamental | PitchBook growth deceleration + corporate client softness | Media | Medio | MEDIUM | PitchBook growth from 12%+ to 7.9%; corporate segment weak in slow deal environment |
| 5 | Fundamental | Sustainalytics/ESG structural decline (anti-ESG political wave) | Alta | Bajo | LOW | <5% of revenue, but brand association risk |
| 6 | Financiero | CRSP acquisition adds $365M goodwill + integration risk | Media | Medio | MEDIUM | ND/EBITDA rises from 0.9x; acquisition track record mixed |
| 7 | Fundamental | Morningstar Wealth segment barely profitable (5% op margin) | Media | Bajo | LOW | ~10% of revenue dragging overall margins; US TAMP wind-down ongoing |
| 8 | Governance | Mansueto insider selling $11.8M in Q4 2025/Q1 2026 | Media | Medio | MEDIUM | Under 10b5-1 plan, still owns 45%; but selling near lows is notable |
| 9 | Valoracion | Q4 earnings tonight -- binary catalyst risk | Alta | Medio | HIGH | Consensus $2.34-2.36 EPS, $627-634M revenue. Miss could push stock to $130-140 |
| 10 | Macro | Bear market reduces AUM-based revenue (~15% of total) | Baja | Medio | LOW | License-based (65%) provides stability |
| 11 | Regulatorio | DBRS NRSRO/ESMA designation risk + credit rating regulatory changes | Baja | Alto | MEDIUM | DBRS is #4, smaller target; but regulatory moat is binary |
| 12 | Fundamental | Concentration risk: Vanguard relationship post-CRSP | Media | Alto | HIGH | 97% of CRSP AUM is Vanguard. Loss of Vanguard relationship would devastate indexing segment |

---

## Top 3 Riesgos Criticos

### 1. CRSP Acquisition: Conflict of Interest Threatens Brand Trust (NOT MENTIONED IN THESIS)

- **Categoria:** Fundamental / Governance
- **Descripcion:** Morningstar completed the $365M acquisition of CRSP from the University of Chicago on February 2, 2026. CRSP indexes underpin $3.2 trillion in assets, with 97% ($3.1T) in Vanguard funds including the world's largest mutual fund (VTSAX/VTI). Morningstar now simultaneously (a) owns the index benchmarks for Vanguard funds, (b) rates those Vanguard funds via Morningstar star ratings, and (c) sells data and analytics to Vanguard and its competitors. This creates a structural conflict of interest that threatens Morningstar's core brand value: being an "impartial third party."
- **Evidencia:** RIABiz Oct 2025 article extensively documented the conflict. Observer Scott MacKillop stated: "The issue is whether Morningstar would provide more favorable analytic treatment to its CRSP customers in order to keep them happy." Morningstar has NOT yet finalized policies on whether it will continue rating CRSP-benchmarked funds. Vanguard uses Morningstar ratings in advertising, creating layered conflicts.
- **Probabilidad:** Media -- Regulatory scrutiny or media exposing bias is plausible over 2-3 years.
- **Impacto si materializa:** HIGH. Morningstar's brand IS its moat. If institutional investors, advisors, or regulators perceive ratings as conflicted, the core Morningstar Direct and fund rating business (which drives ~35% of revenue) is impaired. Estimated downside: 15-25% of revenue at risk if trust erodes, translating to 30-50% stock decline.
- **Mitigante:** Morningstar promises to develop "Chinese wall" policies separating research and commercial activities. Vanguard has extended its CRSP relationship post-acquisition, suggesting they are comfortable with the arrangement for now.
- **Kill condition?:** YES -- If a regulatory investigation into Morningstar's fund ratings objectivity is opened, or if a major institutional client publicly drops Morningstar citing conflict of interest, this should be a kill condition.

### 2. EPS Peak Risk: Normalized Earnings May Be Lower Than Current Trailing

- **Categoria:** Valoracion
- **Descripcion:** The thesis uses a P/E of 18x on trailing EPS of $8.64 (2024) to argue the stock is cheap. However, EPS grew from $1.65 (2022) to $8.64 (2024) -- a 130% increase in 2 years driven by operating leverage recovery from the 2022 trough. The question is whether $8.64 represents normalized earnings or a cyclical peak. If MORN's operating margin trajectory stalls at 20-21% (instead of expanding to 25%+ as the thesis assumes), and revenue growth slows to 6-7%, forward EPS could be $7.50-8.50 rather than $9.50-10.00. On $7.50 normalized EPS at 18x P/E, the stock is fairly valued at $135, not cheap.
- **Evidencia:** (a) Q3 2025 net income declined YoY despite revenue growth, suggesting operating leverage may be plateauing. (b) Simply Wall St analysis notes MORN's 8.5% projected growth is BELOW the market's expected 16% growth, making the current P/E NOT actually cheap in a growth-adjusted context. (c) 2022 was an abnormal trough (margins compressed by investment spending); recovery to 18.5% operating margin may be the "normalization," not the starting point for further expansion. (d) Analyst consensus revenue growth for Q4 is 6.2%, decelerating from 9.7% a year ago.
- **Probabilidad:** Media -- Margin expansion could continue (as the thesis argues), but operating leverage flattening is equally plausible.
- **Impacto si materializa:** Medium-High. If normalized EPS is $7.50-8.00, the bear case FV is $135-145 (not $148 as the thesis claims). This reduces the MoS from the thesis's 32% to 0-10%.
- **Mitigante:** $1B buyback program is accretive at current prices (buying at 18x P/E vs historical 30-40x). Credit segment operating margin expanding rapidly (from 5% to 31% in 2 years). PitchBook has room for margin improvement.
- **Kill condition?:** NO, but should be monitored. If FY2025 operating margin comes in below 20% or 2026 guidance implies margin stagnation, the valuation thesis weakens significantly.

### 3. Vanguard Concentration Risk in CRSP Index Business

- **Categoria:** Fundamental
- **Descripcion:** 97% of assets tracking CRSP indexes ($3.1 trillion of $3.2 trillion) are in Vanguard funds. This makes Morningstar's newly acquired $55-65M indexing revenue stream almost entirely dependent on a single client relationship. Vanguard has extended its relationship post-acquisition, but if Vanguard decided to create its own proprietary index (as it has done in other areas) or switch to an alternative, the entire CRSP revenue stream would evaporate.
- **Evidencia:** Morningstar announced extending the Vanguard relationship on Feb 2, 2026, the same day it closed the CRSP acquisition. While this is positive near-term, it does not eliminate the structural concentration. Vanguard is known for cost-cutting and in-sourcing: it previously brought investment management in-house and has been reducing external index licensing costs across its fund complex.
- **Probabilidad:** Baja -- Vanguard has no incentive to switch immediately, and CRSP data is embedded in decades of academic research. But over a 5-10 year horizon, this risk is non-trivial.
- **Impacto si materializa:** Medium. $55-65M revenue loss would be ~2.5% of total revenue, not existential. But the $365M acquisition price would represent a near-total write-down of goodwill, and the reputational damage from a "failed" high-profile acquisition would be significant.
- **Mitigante:** CRSP indexes have deep academic heritage (60+ years). Switching would require fund boards, regulators, and investors to approve benchmark changes. This creates significant inertia.
- **Kill condition?:** NO.

---

## Riesgos NO Mencionados en Thesis

| Riesgo | Severidad | Mencionado en thesis? | Comentario |
|--------|-----------|----------------------|------------|
| CRSP acquisition conflict of interest | HIGH | NO | Thesis does not mention this Feb 2026 acquisition AT ALL. This is a material omission. The $365M deal was completed 10 days ago and creates structural conflicts with fund rating business. |
| Vanguard concentration (97% of CRSP AUM) | MEDIUM | NO | Single-client dependency for acquired revenue stream. |
| EPS may be at cyclical peak, not trough | HIGH | Minimizado | Thesis frames 18x P/E as "cheap" without adequately addressing that $8.64 EPS may be above trend. Q3 net income declined YoY despite revenue growth. |
| Mansueto selling $11.8M in shares near lows | MEDIUM | NO | Thesis says "Kapoor not selling" and "45% insider ownership" but does not mention Mansueto sold 58,905 shares ($11.8M) in Q4/Q1. Under 10b5-1 plan but still notable at 52-week lows. |
| Sustainalytics/ESG: $84B fund outflows in 2025 | LOW | Minimizado | Thesis mentions ESG headwind but calls it <5% of revenue. The $84B in 2025 outflows (first annual net redemption since tracking began) and anti-ESG US administration signal structural, not cyclical, decline. |
| PitchBook corporate client weakness | MEDIUM | Minimizado | Thesis projects steady 8% growth. PitchBook Q3 showed "continued softness in the corporate client segment, especially among smaller firms" during slow deal activity. If PE/VC deal flow stalls, PitchBook growth could decelerate further. |
| Wealth segment drag: US TAMP wind-down | LOW | NO | Morningstar Wealth is winding down its US Turnkey Asset Management Platform. $4.4M in Q3 retention/commission costs related to wind-down. Transition risk. |
| Q4 earnings tonight: binary catalyst risk | HIGH | Mentioned as catalyst, not as risk | Thesis frames Q4 as upside catalyst. But a miss on $2.34-2.36 EPS consensus or weak 2026 guidance could push stock 10-15% lower. |
| Growth deceleration: Q4 consensus 6.2% revenue growth (vs 9.7% year-ago) | MEDIUM | Minimizado | Thesis uses 8% forward growth. Q4 consensus is 6.2%. If full-year 2025 comes in at 7-8% and 2026 guidance is 6-7%, the "8-10% organic grower" narrative breaks. |

---

## Kill Conditions Sugeridas

Based on my independent findings, these kill conditions should be ADDED to the thesis:

1. **CRSP Conflict Kill Condition:** If a regulatory body (SEC, FINRA) opens a formal investigation into Morningstar's fund ratings objectivity related to CRSP-benchmarked funds, or if a major institutional client publicly drops Morningstar data citing conflict of interest concerns, EXIT immediately. The brand IS the moat; a regulatory stain on objectivity is existential.

2. **Vanguard Relationship Kill Condition:** If Vanguard announces intention to create or adopt proprietary/alternative indexes to replace CRSP benchmarks for its major funds, the $365M CRSP acquisition becomes an impairment candidate. EXIT on announcement.

3. **Revenue Growth Stagnation Kill Condition:** If organic revenue growth falls below 5% for 2 consecutive quarters (not just one), the "secular compounder" thesis is invalidated. The thesis assumes 8% growth; if growth normalizes to 5-6%, the DCF fair value drops to $150-165 (near current price, eliminating MoS).

---

## Riesgo Agregado

- **Numero de riesgos HIGH+CRITICAL:** 4 (CRSP conflict, EPS peak, Q4 binary, Vanguard concentration)
- **Riesgos correlacionados?:** YES.
  - CRSP conflict + Vanguard concentration are directly linked: both stem from the CRSP acquisition. If Vanguard becomes uncomfortable with the conflict, both risks materialize simultaneously.
  - EPS peak + growth deceleration are correlated: if revenue growth slows and margins plateau, EPS normalizes lower and the valuation thesis unravels.
- **Risk Score Final: MEDIUM**

**Rationale for MEDIUM (not HIGH):** Despite 4 HIGH-scored risks, the mitigants are substantial:
- CRSP conflict: Industry standard for financial data companies to have multiple roles (S&P Global rates debt AND provides indices AND sells data). Morningstar's situation is more acute but not unprecedented.
- EPS peak: The $1B buyback program at current prices is genuinely accretive. Credit segment margin expansion is real and ongoing.
- Q4 binary: This is a near-term timing risk, not a structural thesis risk.
- The core business (Morningstar Direct + PitchBook + Credit) has genuine switching costs, data network effects, and pricing power.

However, if Q4 earnings disappoint AND the CRSP conflict generates media/regulatory attention, the risk score would escalate to HIGH.

---

## META-REFLECTION

### Dudas/Incertidumbres

- **CRSP conflict severity:** I identified this as the top risk, but I am uncertain how the market and regulators will actually weigh this. The financial data industry has many overlapping roles (S&P Global both rates bonds and provides indices). It is possible this concern is overweighted in my analysis. Conversely, Morningstar's SPECIFIC brand as "independent fund rater" makes the conflict more acute than for S&P Global.
- **EPS normalization range:** I estimated $7.50-8.50 as a possible normalized EPS, but without detailed segment-level operating leverage analysis, this is a rough estimate. The Q4 results (tonight) will provide critical data.
- **Insider selling interpretation:** Mansueto's 10b5-1 plan was adopted November 2024 when the stock was above $300. The selling is automatic, not discretionary. This may fully explain it. But the OPTICS of a founder selling $11.8M near 52-week lows are not great for sentiment.

### Riesgos que Podrian Estar Subestimados

- **AI disruption:** I classified this as MEDIUM, but if generative AI tools (ChatGPT, Gemini, Perplexity) can produce investment research summaries at zero marginal cost, the question becomes whether advisors will pay for Morningstar's curated analysis when AI provides "good enough" alternatives. The 30% probability the thesis assigns to "being wrong on AI" may be optimistic; a 40-50% probability is more appropriate given the pace of AI advancement in 2025-2026. The Morningstar Intelligence Engine is a defensive response, not a competitive advantage.
- **Growth deceleration may be structural, not cyclical:** The thesis frames the slowdown from 12% to 8% as "normalization." But what if the financial data TAM is saturating? Bloomberg, S&P Global, MSCI, and FactSet all compete for the same institutional budgets. MORN is the smallest player, and pricing pressure in a maturing market could compress growth to 5-6% permanently.

### Discrepancias con Thesis

1. **CRSP acquisition completely absent from thesis.** This is the most significant omission. A $365M acquisition completed 10 days before the analysis that creates a structural conflict of interest should have been a central topic of discussion.
2. **Thesis says "Insider selling massive: NO" and "Kapoor not selling."** While technically accurate that Kapoor (CEO) is not selling, Mansueto (Chairman, 45% owner) sold $11.8M in shares in the last quarter, including sales in February 2026 at prices between $168-188. The thesis should acknowledge this.
3. **Thesis frames 18x P/E as "historically cheap."** This is true relative to peers (SPGI 37x, MSCI 42x), but the thesis does not adequately address that MORN's lower margins (21% operating vs SPGI 47%) and lower growth (8% vs MSCI 15%) may justify a structural discount. MORN at 18x with 8% growth is not obviously cheaper than SPGI at 37x with 14% growth on a PEG basis (MORN PEG 2.25 vs SPGI PEG 2.64).
4. **Thesis's bear case FV of $148 may be optimistic.** If operating margins stagnate at 20% and growth decelerates to 6%, using the same DCF framework, FV could be $130-140, implying 10-15% downside from current price.

### Sugerencias para el Sistema

- **CRSP acquisition should trigger a follow-up analysis.** The fundamental-analyst should be asked to incorporate the CRSP acquisition into the thesis, including revenue impact, goodwill analysis, and conflict of interest discussion.
- **Insider selling data should be a standard check in the fundamental-analyst's process.** The thesis template should include a mandatory section on recent insider transactions (not just ownership level).
- **PEG ratio as sanity check:** When comparing P/E multiples to peers, the thesis should also include PEG ratios to normalize for growth differences. A lower P/E with lower growth is not necessarily cheaper.

### Preguntas para Orchestrator

1. The CRSP acquisition conflict of interest is a material risk NOT covered in the thesis. Should the fundamental-analyst be asked to revise the thesis to address this, or should we wait for Q4 results first and then do a comprehensive R1 update?
2. Given that Q4 results report TONIGHT (after close Feb 12), should R2 (devil's advocate) be deferred until we have post-earnings data, or should it proceed immediately?
3. The Mansueto insider selling pattern -- should we investigate whether the 10b5-1 plan has acceleration clauses or is on a fixed schedule? The selling prices ($168-188) are substantially below current levels ($155), which suggests these sales have already occurred.

---

**Analysis Date:** 2026-02-12
**Analyst:** risk-identifier (R1)
**Next Steps:** R2 (devil's-advocate), then R4 (investment-committee)
